Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 3953-3956

  Sawyer, J Scott ^a   Anderson, Bryan D ^a   Beight, Douglas W ^a   Campbell, Robert M ^a   Jones, Michael L ^a   Herron, David K ^a   Lampe, John W ^a   McCowan, Jefferson R ^a   McMillen, William T ^a   Mort, Nicholas ^a   Parsons, Stephen ^a   Smith, Edward C R ^a   Vieth, Michal ^a   Weir, Leonard C ^a   Yan, Lei ^a   Zhang, Faming ^a   Yingling, Jonathan M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (QUINOLIN 4 YL)PYRAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CLAISEN CONDENSATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; DECARBOXYLATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HYDROGEN BOND; IN VITRO STUDY; MINK; MOUSE; NONHUMAN; PHARMACOPHORE; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; BENZENE DERIVATIVES; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MINK; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037620888     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205705     Document Type: Article

References (23)

1. (a) Huse, M.; Muir, R. W.; Xu, L.; Chen, Y.-G.; Kuriyan, J.; Massague, J. The TGFβ Receptor Activation Process: An Inhibitor- to Substrate-Binding Switch. Mol. Cell 2001, 8, 671-682.
2. (b) Moustakas, A.; Soucheinytskyi, S.; Heldin, C.-H. Smad Regulation in TGF-β Signal Transduction. J. Cell Sci. 2001, 114, 4359-4369.
3. (c) Zimmerman, C. M.; Padgett, R. W. Transforming Growth Factor β Signaling Mediators and Modulators. Gene 2000, 249, 17-30.
4. Kim, S. J.; Park, K.; Koeller, D.; Kim, K. Y.; Wakefield, L. M.; Sporn, M. B.; Roberts, A. B. Post-transcriptional Regulation of the Human Transforming Growth Factor-β1 Gene. J. Biol. Chem. 1992, 267 (19), 13702-13707.
5. Cordeiro, M. F. Beyond Mitomycin: TGF-β and Wound Healing. Prog. Retinal Eye Res. 2002, 21, 75-89.
6. Masliah, E.; Ho, G.; Wyss-Coray, T. Functional Role of TGFβ in Alzheimer's Disease Microvascular Injury: Lessons from Transgenic Mice. Neurochem. Int. 2001, 39, 393-400.
7. McCaffrey, T. A. TGF-βs and TGF-β Receptors in Atherosclerosis. Cytokine Growth Factor Rev. 2000, 11, 103-114.
8. Derhaschnig, U.; Shehata, M.; Herkner, H.; Bur, A.; Woisetschläger, C.; Laggner, A. N.; Hirschl, M. M. Increased Levels of Transforming Growth Factor-β1 in Essential Hypertension. Am. J. Hypertens. 2002, 15, 207-211.
9. Chamberlain, J. Transforming Growth Factor-β: A Promising Target for Anti-Stenosis Therapy. Cardiovasc. Drug Rev. 2001, 19 (4), 329-344.
10. (a) Akhurst, R. J.; Derynk, R. TGF-β Signaling in Cancer - A Double-Edged Sword. Trends Cell Biol. 2001, 11 (11), S44-S51.
11. (b) Derynk, R.; Akhurst, R. J.; Balmain, A. TGF-β Signaling in Tumor Suppression and Cancer Progression. Nat. Genet. 2001, 29, 117-129.
12. (c) Massague, J.; Blain, S. W.; Lo, R. S. TGF-β Signaling in Growth Control, Cancer, and Heritable Disorders. Cell 2000, 103, 295-309.
13. (d) de Caestecker, M. P.; Piek, E.; Roberts, A. B. Role of Transforming Growth Factor-β Signaling in Cancer. J. Natl. Cancer Inst. 2000, 92 (17), 1388-1402.
14. Wieser, R.; Wrana, J. L.; Massague, J. GS Domain Mutations That Constitutively Activate TβR-1, the Downstream Signaling Component in the TGF-β Receptor Complex. EMBO J. 1995, 14 (10), 2199-2208.
15. Wrana, J. L.; Attisano, L.; Carcamo, J.; Zentella, A.; Doody, J.; Laiho, M.; Wang, X. F.; Massague, J. TGFβ Signals through a Heteromeric Protein Kinase Receptor Complex. Cell 1992, 71, 1003-1014.
16. Leof, E. B.; Proper, J. A.; Goustin, A. S.; Shipley, G. D.; DiCorleto, P. E.; Moses, H. L. Induction of c-sis mRNA and Activity Similar to Platelet-Derived Growth Factor by Transforming Growth Factor Beta: A Proposed Model for Indirect Mitogenesis Involving Autocrine Activity. Proc. Natl. Acad. Sci. U.S.A. 1986, 83 (8), 2453-2457.
17. (a) Minami, N.; Sato, M.; Hasumi, K.; Yamamoto, N.; Keino, K.; Matsui, T.; Kanada, A.; Ohta, S.; Saito, T.; Sato, S.; Asagarasu, A.; Doi, S.; Kobayashi, M.; Sato, J.; Asano, H. Preparation of Substituted Pyrazole Compounds as p38 MAP Kinase Inhibitors. PCT Int. Appl. WO 0075131, 2000.
18. (b) Anantanarayan, A.; Clare, M.; Collins, P.; Crich, J.; Devraj, R.; Flynn, D. L.; Geng, L.; Graneto, M. J.; Hanau, C. E.; Hanson, G. J.; Hartmann, S. J.; Hepperle, M.; Huang, H.; Khanna, I. K.; Koszyk, F. J.; Liao, S.; Metz, S.; Partis, R. A.; Perry, T. D.; Rao, S. N.; Selness, S. R.; South, M. S.; Stealey, M. A.; Talley, J. J.; Vazquez, M. L.; Weier, R. M.; Xu, X.; Yu, Y. Preparation of Heteroarylpyrazoles as p38 Kinase Inhibitors. PCT Int. Appl. WO 0031063, 2000.
19. (c) Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, S.-S. Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases. Curr. Med. Chem. 1999, 6, 807-823.
20. This 4-fluorophenyl/pyridin-2-yl substitution pattern has been employed recently in two different scaffolds developed for the selective inhibition of the TGF-β1 receptor kinase domain. (a) Callahan, J. F.; Burgess, J. L.; Fornwald, J. A.; Gaster, L. M.; Harling, J. D.; Harrington, F. P.; Heer, J.; Kwon, C.; Lehr, R.; Mather, A.; Olson, B. A.; Weinstock, J.; Laping, N. J. Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type I Receptor (ALK5). J. Med. Chem. 2002, 45, 999-1001.
21. (b) Laping, N. J.; Grygielko, A.; Mathur, A.; Butter, S.; Bomberger, J.; Tweed, C.; Martin, W.; Fornwald, J.; Lehr, R.; Harling, J.; Gaster, J. F.; Olson, B. A. Inhibition of Transforming Growth Factor (TGF)-β1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542. Mol. Pharmacol. 2002, 62 (1), 58-64.
22. (c) Inman, G. J.; Nicolas, F. J.; Callahan, J. F.; Harling, J. D.; Gaster, L. M.; Reith, A. D.; Laping, N. J.; Hill, C. S. SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002, 62 (1), 65-74.
23. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in MAP Kinases. Structure (London) 1998, 6 (9), 1117-1128.